Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.42 |
| ▸ | DDT | P30046 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976395 | 0.93 | RXFP1 (0.46) | RXFP1TMPRSS4RAF1BRAFTP53 | |
| SCHEMBL4465214 | 0.93 | RXFP1 (0.47) | RXFP1TMPRSS4RAF1BRAFMAPT | |
| SCHEMBL3042696 | 0.93 | RXFP1 (0.47) | RXFP1TMPRSS4RAF1BRAFTP53 | |
| SCHEMBL4973402 | 0.91 | TP53 (0.50) | RXFP1TP53MAPTKDM4EPOLB | |
| SCHEMBL4972906 | 0.88 | RXFP1 (0.47) | RXFP1TP53MAPTPOLBKDR | |
| SCHEMBL4975964 | 0.88 | RXFP1 (0.48) | RXFP1TMPRSS4RAF1BRAFTP53 | |
| SCHEMBL4976902 | 0.88 | RXFP1 (0.49) | RXFP1TMPRSS4TP53MAPTPOLB | |
| SCHEMBL4977861 | 0.86 | RXFP1 (0.47) | RXFP1TMPRSS4RAF1BRAFTP53 | |
| SCHEMBL3034826 | 0.86 | RXFP1 (0.47) | RXFP1TMPRSS4RAF1BRAFTP53 | |
| SCHEMBL4462916 | 0.86 | RXFP1 (0.47) | RXFP1TMPRSS4RAF1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RXFP1 1473/4885TMPRSS4 832/4885RAF1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.